Wegovy and Liver Health — Monitoring Guide for Australian Patients

Semaglutide — the active ingredient in Wegovy — acts on the liver through several mechanisms simultaneously:

Reduction in liver fat. Weight loss from Wegovy significantly reduces visceral fat, including liver fat. Clinical trials demonstrate 30–40% reduction in liver fat content within the first six months of therapy in patients with MASLD.

Improvement in insulin sensitivity. Insulin resistance is a primary driver of fatty liver disease. As Wegovy improves insulin sensitivity, the liver receives less metabolic stimulus to accumulate fat and produce inflammatory cytokines.

Direct hepatic action. Secondary analyses of the ESSENCE trial presented at AASLD 2025 showed Wegovy was associated with resolution in liver injury while improvements in liver scarring trended to favour semaglutide across a spectrum of weight loss thresholds — suggesting direct hepatic effects beyond weight loss alone.

Normalisation of liver enzymes. ALT and AST levels, which indicate liver cell damage, frequently normalise during Wegovy treatment. Many patients who previously showed signs of liver stress find their enzyme levels returning to healthy ranges within the first year of therapy.

The net effect for most patients is liver improvement — not liver harm. This is the consistent finding across clinical trials and real-world studies.

In April 2026, the TGA granted provisional approval for Wegovy for the following new indication: treatment of adults with non-cirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3).

This makes Wegovy the first GLP-1 medication approved in Australia to treat liver disease directly — not just as a side effect of weight loss, but as a primary therapeutic target.

The TGA's provisional approval is based on evidence showing improvements in liver inflammation and scarring. MASH is too often diagnosed after significant liver damage has occurred, according to Professor Jacob George, who led the study underpinning the decision.

The approval is provisional — meaning Novo Nordisk must provide confirmatory long-term data on outcomes including cirrhosis, liver transplantation, and liver-related mortality from the ongoing ESSENCE trial.

Who qualifies: adults with biopsy-confirmed or elastography-confirmed MASH at fibrosis stages F2 or F3, in a non-cirrhotic liver, prescribed by or in consultation with a hepatologist or gastroenterologist.

Who does not qualify under this indication: patients with simple MASLD (fat accumulation without inflammation), patients at fibrosis stage F1 or F4 (cirrhosis), or patients being prescribed Wegovy solely for weight management.

Current evidence suggests that clinically significant liver enzyme elevations are uncommon with Wegovy. Serious drug-induced liver injury is very rare. The weight loss achieved with semaglutide may improve liver enzyme levels in individuals with fatty liver disease.

A case report published in September 2025 described a rare case of drug-induced liver injury associated with semaglutide, presenting with transient liver failure one month after starting the medication in a middle-aged woman with no prior liver disease identified on standard testing. This is a rare event — but it reinforces the importance of baseline liver function testing and clinical vigilance during the early months of treatment.

Recommended monitoring protocol for Wegovy:

Before starting: full liver function panel (ALT, AST, GGT, ALP, bilirubin, albumin, platelets) and FIB-4 calculation.

At 3 months: repeat ALT and AST to detect any early enzyme changes.

At 6 months: if FIB-4 was indeterminate at baseline, consider liver elastography to assess fibrosis status.

At 12 months: repeat full liver function panel and FIB-4 recalculation.

Ongoing: annual liver function monitoring while continuing Wegovy.

Symptoms that require urgent review:

Jaundice (yellowing skin or eyes), dark urine, pale or clay-coloured stools, severe right upper abdominal pain, or unexplained persistent nausea and vomiting within the first months of starting Wegovy should prompt same-day GP contact.

Both Wegovy and Ozempic contain semaglutide. The clinical difference for liver health is the dose.

Wegovy at 2.4mg weekly — the ESSENCE trial dose — produced 62.9% MASH resolution in phase 3 trial participants. This is the dose with TGA approval for MASH treatment.

Ozempic at 1mg weekly — the standard diabetes dose — also shows liver benefits in clinical practice and observational studies, but at a lower magnitude than the higher Wegovy dose. The liver benefits of semaglutide are dose-dependent.

For patients with established MASH at F2–F3 fibrosis who need treatment now, Wegovy at 2.4mg is the appropriate choice under the new TGA indication. For patients managing type 2 diabetes with comorbid MASLD, Ozempic provides real hepatic benefit — but upgrading to Wegovy may be worth discussing with a specialist.

Wegovy's PBS (Pharmaceutical Benefits Scheme) status is evolving. As of mid-2026:

Wegovy for weight management in obesity: received a positive PBAC recommendation for a narrow group of very high-risk patients, but broad PBS subsidy for weight management is not yet available. Most patients pay privately — approximately $200–$400 per month depending on pharmacy and dose.

Wegovy for MASH: the PBS pathway for the new MASH indication is a separate process and is currently being evaluated. Discuss the current subsidy status with your prescribing specialist, as this space is changing rapidly.

For patients prescribed Wegovy under the MASH indication, the clinical urgency of treatment — given the risk of progression to cirrhosis in untreated F2–F3 MASH — may support a specialist argument for subsidy that does not yet apply to weight management prescriptions.

The FIB-4 score is the starting point. Calculated from your age, ALT, AST, and platelet count — all available from a standard blood panel — it provides a risk stratification for significant liver fibrosis.

If your FIB-4 is indeterminate (1.3–2.67), or if you have risk factors for MASLD (obesity, type 2 diabetes, metabolic syndrome, alcohol use) and have never been assessed, liver elastography is the recommended next step.

A liver elastography scan takes 10–15 minutes, involves no radiation or injection, and provides immediate results in kPa (liver stiffness) and dB/m (liver fat content). Results below 8 kPa are generally reassuring. Values above 12–13 kPa warrant specialist review.

Find a liver elastography clinic near you →